中美贸易摩擦在医药领域，已经影响到两国之间正常的科研学术、资金及人才交流。近日，超过百名美国医药领域领导人士，包括诺贝尔奖得主、顶尖科研机构科学家、生物科技企业企业家及风险投资公司投资家，发布联名信指出近期美国官方近期针对美国境内中国科学家的一系列措施，将威胁美国在生物医学领域的领导地位，要求停止这一系列行动。
中美贸易摩擦不断，政策高压已经蔓延至生物医药领域。去年10月开始，美国外国投资委员会（CFIUS）收紧外国企业和资本进入到27个美国敏感技术领域政策，其中包括生物医药行业。随即，到2019年中国赴美投资生物医药的资本锐减，多项投资申请被驳回。
而到今年，政策审查更深入到在美生物医药领域的中国科学家。近期，据《彭博商业周刊》报道，今年1月，屡获殊荣已经入籍美国的华裔流行病学专家feng Wu，悄悄地离开了任职多年的德克萨斯大学安德森癌症中心(Anderson Cancer Center)公共卫生与转化基因组学中心。被迫辞职前她在该中心担任主任职位，安德森癌症中心对她进行了三个月的调查，调查原因是她接受了中国医疗机构六个咨询职位。
类似的被迫辞职事件，同样发生在安德森癌症中心的另外三位顶尖华裔科学家身上。美国MD安德森癌症中心出于间谍活动考虑，将把三名华人科学家赶出院系。
美国政策层面，对于中国生物医药科学家的针对性措施，已经使得美国生物医药界各个层面感受到了强烈的压力。2019年8月21日，由Ovid Therapeutics公司CEO Jeremy Levin起草，包括诺贝尔奖得主、顶尖科研机构科学家、生物科技企业企业家及风险投资公司投资家等超过百名美国医药领域领导人士联名发布了公开信，以回应近期美国官方及大学针对中国生物医药科学家的措施。
E药经理人对公开信全文进行编译，原文如下：
中国科学家与美国在生物医学领域的领导地位
引言：近期美国境内政府及大学对中国科学家的针对性措施将严重威胁美国在生物医学领域的领导地位。
我们是这封公开信的联名者，也是美国生物医药研发学术领域和产业领域的领导者。我们担心美国政府机构及大学近期对对留美中国科学家所采取的行动，将会威胁到美国在生物医学领域的领导地位。
最近一段时间，相当数量来自中国的生物医药科学家以及美籍华裔生物医药科学家，被大学解雇，这在美国的生物医学界引发了相当大的不确定性和恐慌。
让我们明确一点：我们必须绝对防范外国间谍活动和知识产权盗窃，并起诉那些参与其中的人，无论其来自哪个国家。
但是，更广泛地限制中美两国科学家及公司之间合作将极大损害美国国家利益;而限制美籍华裔科学家接受政府研究基金资助或受雇于NIH，其对美国国家利益的损害亦复如是。
在两国相互敌对时，一国领导人经常诋毁“另一国”。但我们所面临“战争”，需要跨越这种诋毁，集结来自于世界各地的医药科学研究者，来共同对抗人类共同的“敌人”—疾病：癌症，免疫疾病，阿尔茨海默病，感染疾病，人类所面对的疾病不胜枚举，此举例仅为沧海一粟。
而将任何一国的医药科学研究者排除在外，无疑将限制我们全面赢得这场人类“战争”的能力。
美国作为移民国家，其开放性对在生物医药研发上取得世界领导地位至关重要。美国所吸引到的来自全世界的优秀，多样化人才，极大丰富了美国的经济和社会。作为一个例子，我们的初步研究表明，自1999年以来，中国医药研究者已经在美国取得了超过40万项专利，2018年约28％的美国生物医学科学出版物收录了中国作者的论文。
而目前萦绕在美国生物医药领域的恐怖气氛，将使得无数优秀的中国科学家不得不永远离开美国。并且在此境遇之下，来自其他国家在美国工作的科学家也不得不怀疑，自己将会是下一个目标。
我们还注意到，生物医药领域学术研究绝大多数结果并不涉及国家机密;但这些学术研究的公开出版以及学术研究人员公开交流，是我们成功对抗人类共同敌人疾病的关键基石。正如美国独立宣言起草人托马斯.杰斐逊写道：“传播思想，无损于思想的传播者。同样，点燃蜡烛照亮他人者，也不会给自己带来黑暗。”
我们非常赞同Nature，Nature Biotechnology和前NIH主任Elias Zerhouni的观点，他呼吁政策既要保护美国知识产权，同时也能继续促进多方协作，以推动科学进步和提高治愈疾病的能力。至少，大学必须有效地沟通并始终如一地应用其管理科学合作和知识产权义务的规则，他们以及政府机构在指责科学家渎职或试图将他们从职位上解雇时，必须明确证明其行为是正当的。
罗纳德.里根说过：“我们之所以能在众多国家中脱颖而出引领潮流，是因为我们从世界各个国家和地区吸引人才，”并且，“如果我们关闭对新美国人的大门，我们很快在世界上失去领导力。”
这些想法在生物医药科学领域中尤其重要。如果我们想要在人类征服疾病的道路中占据上风，我们最可靠的途径是接纳任何能够有所贡献的人，无论其来自哪个国家，宗教，种族，性别或其他身份。美国的生物医学界代表着美国建国原则所包含的多样性和团结的原则，没有这些原则，我们的领导确实很快就会失去。
附联名人名单：
Decibel Therapeutics, Boston, Massachusetts, USA
Steven Holtzman
Acorda Therapeutics, Ardsley, New York, USA
Ron Cohen
Ovid Therapeutics, New York, New York, USA
Jeremy M. Levin
Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
John M. Maraganore
Blueprint Medicines, Cambridge, Massachusetts, USA
Jeff Albers
Northeastern University, Boston, Massachusetts, USA
Joseph E. Aoun
Chicago Biomedical Consortium, Northwestern University, Chicago, Illinois, USA
James E. Audia, PhD
AVEO Oncology, Cambridge, Massachusetts, USA
Michael P. Bailey
Atlas Venture, Cambridge, Massachusetts, USA
Peter Barrett
MIT/Whitehead Institute/HHMI, Cambridge, Massachusetts, USA
David Bartel
BioMarin Pharmaceutical, Inc., Novato, California, USA
Jean-Jacques Bienamie
Cytokenetics, Inc., South San Francisco, California, USA
Robert I. Blum
Boston, Massachusetts, USA; Vertex Pharmaceuticals, Inc. (retired), Boston, Massachusetts, USA
Joshua Boger, PhD
Alnylam, Magenta, Kaleido, Cambridge, Massachusetts, USA
Michael W. Bonney
Atlas Venture, Cambridge, Massachusetts, USA
Bruce Booth, Phil
Equillium, Inc., La Jolla, California, USA
Daniel M Bradbury
New York, New York, USA; Sanofi, SA (retired), Paris, France
Olivier Brandicourt, MD
Harvard Medical School, Cambridge, Massachusetts, USA
Eugene Braunwald, MD
Morphic Therapeutics, Waltham, Massachusetts, USA
Gustav Christensen
Flexion Therapeutics, Burlington, Massachusetts, USA
Michael D. Clayman, MD
Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
Charles L. Cooney
Gerald Cox Rare Care Consulting, LLC, Boston Children’s Hospital/Harvard Medical School, Greater
Boston, Massachusetts, USA
Gerald F. Cox, MD, PhD
CGIR, LLC, Savannah, Georgia, USA
Sally J. Curley, IRC
Xencor, Inc., Monrovia, California, USA
Bassil Dahiyat
MD Anderson Cancer Center, Dept. of Cancer Biology, Houston, Texas, USA
Ronald A. DePinho, MD
5AM Ventures, Boston, Massachusetts, USA
John Diekman
MaxCyte, Inc., Gaithersburg, Maryland, USA
Douglas Doerfler
Excision BioTherapeutics, Philadelphia, Pennsylvania, USA
Daniel Dornbusch
Aldeyra Therapeutics, Lexington, Massachusetts, USA
Richard H. Douglas, PhD
H Lundbeck A/S, Copenhagen, Denmark
Deborah Dunsire, MD
Novus Therapeutics, Inc., Irvine, California, USA
Gregory J. Flesher
Atlas Venture, Cambridge, Massachusetts, USA
Jean-Francois Formela
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Kaye I. Foster-Cheek
Apellis Pharmaceuticals, Louisville, Kentucky, USA
Cedric Francois
TEQLA Therapeutics Inc., Boston, Massachusetts, USA
Michael P. Franken
Blaze Bioscience Inc., Seattle, Washington, USA
Heather Franklin
enGage Biotech Consulting, Bryn Mawr, Pennsylvania, USA
L. Patrick Gage, PhD
Stanford University, Stanford, California, USA
Phyllis Gardner, MD
Orchard Therapeutics, Boston, Massachusetts, USA
James A. Geraghty
Evelo Biosciences, Cambridge, Massachusetts, USA
Simba Gill
ARCH Venture Partners, Chicago, Illinois, USA
Steven Gillis
The Column Group, San Francisco, California, USA
David V. Goeddel
Revolution Medicines, Inc., Redwood City, California, USA
Mark Goldsmith, MD, PhD
Intarcia Therapeutics, Inc., Boston, Massachusetts, USA
Kurt Graves
Gray Strategic Advisors, LLC, New York, New York, USA
Mary Ann Gray, PhD
Atlas Venture, Cambridge, Massachusetts, USA
David Grayzel
Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Barry Greene
Immunogen, Waltham, Massachusetts, USA
Richard J. Gregory, PhD
Carol Greve-Philips Consulting, LLC, Sharon, Massachusetts, USA
Carol Greve-Philips
Imbria Pharmaceuticals, San Diego, California, USA
David-Alexandre Gros, MD
Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts, USA; Food & Drug Administration (2009-2015), Silver Spring Maryland, USA
Margaret A. Hamburg, MD
Science History Institute, Philadelphia, Pennsylvania, USA
Michael Hammerschmidt
Gossamer Bio, San Diego, California, USA
Faheem Hasnain
Nkarta Therapeutics, Redwood City, California, USA
Paul J. Hastings
Redpin Therapeutics, New York, New York, USA
Elma S. Hawkins
Incyte, Wilmington, Delaware, USA
Hervé Hoppenot, PhD
ProMIS Neurosciences, Toronto, Onterio, Canada
Johanne Kaplan, PhD
Virion Biotherapeutics, London, United Kingdom
Vanessa King, PhD
RA Capital Management, LLC, Boston, Massachusetts, USA
Peter Kolchinsky
Broad Institute of MIT & Harvard, Cambridge, Massachusetts, USA
Eric S. Lander
Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
Robert Langer
LaVoieHealthScience, Boston, Massachusetts, USA
Donna L. LaVoie
Kaleido Biosciences, Inc., Lexington, Massachusetts, USA
Alison Lawton
Decibel Therapeutics, Boston, Massachusetts, USA
John J. Lee
Deerfield Management, New York, New York, USA
Jonathan S. Leff
GlaxoSmithKline, Collegeville, Pennsylvania, USA
John Lepore, MD
Bluebird Bio, Cambridge, Massachusetts, USA
Nick Leschly
Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA
Judy Lieberman
Erasca, San Diego, California, USA
Johnathan Lim
Broad Institute/HHMI/Harvard University, Cambridge, Massachusetts, USA
David R. Liu
MIT/Whitehead Institute, Cambridge, Massachusetts, USA
Harvey Lodish
Assembly Biosciences, Carmel, Indiana, USA
Uri Lopatin, MD
Global Blood Therapeutics, South San Francisco, California, USA
Ted W. Love, MD
Scholar Rock, Cambridge, Massachusetts, USA
Nagesh K. Mahanthappa, PhD, MBA
Akili Interactive, Boston, Massachusetts, USA
W. Eddie Martucci, PhD
Imara, Inc, Cambridge, Massachusetts, USA
James McArthur, PhD
Pear Therapeutics, Boston, Massachusetts, USA
Corey M. McCann, MD, PhD
CytomX Therapeutics Inc., South San Francisco, USA
Sean McCarthy, DPhil
Genzyme Corporation, Boston, Massachusetts, USA (retired)
David McLachlan
HHMI/University of Massachusetts Medical School, Worcester, Massachusetts, USA
Craig Mello
Conatus Pharmaceuticals Inc., San Diego, California, USA
Steven J. Mento, PhD
Arbutus Biopharma and CytomX Therapeutics, San Francisco, California, USA
James Meyers
Third Rock Ventures, Boston, Massachusetts, USA
Rachel Meyers
REGENXBIO Inc., Rockville, Maryland, USA
Ken Mills
Cognition Therapeutics, Inc., Pittsburg, Pennsylvania, USA
Kenneth I. Moch
CODA Biotherapeutics, South San Francisco, California, USA
Michael Narachi
Polaris Partners, Boston, Massachusetts, USA
Amir Nashat
Sutro Biopharma, Inc., South San Francisco, California, USA
William J. Newell
EcoR1 Capital, LLC, San Francisco, California, USA
Oleg Nodelman
Vedanta Biosciences Inc., Cambridge, Massachusetts, USA
Bernat Olle, PhD
BioVentures Investors, Wellesley, Massachusetts, USA
John E. Osborn
Life Science Cares, Cambridge, Massachusetts, USA
Rob Perez
OncoPep, Inc., North Andover, Massachusetts, USA
Doris Peterkin
Accendo, Boston, Massachusetts, USA
Alice Lin Pomponio
Intercept Pharma, New York, New York, USA
Mark Pruzanski, MD
Ten Bridge Communications, Boston, Massachusetts, USA
Dan Quinn
Ardelyx, Inc., Fremont, California, USA
Michael G. Raab
Noventia Pharma, Forli, Italy
Massimo Radaelli
Ovid Therapeutics, New York, New York, USA
Amit Rakhit, MD, MBA
Encoded Therapeutics, South San Francisco, California, USA
Kartik Ramamoorthi, PhD
Neurocrine Biosciences Inc., Fate Therapeutics, Daré Biosciences, San Diego, California, USA
William Rastetter
Atlas Venture, Cambridge, Massachusetts, USA
Jason P. Rhodes
NGM Biopharmaceuticals, Inc., South San Francisco, California, USA
William J. Rieflin
Flagship Pioneering, Cambridge, Massachusetts, USA
Michael Rosenblatt, MD
Synergenics, LLC, San Francisco, California, USA
William J. Rutter
Venrock, Palo Alto, California, USA
Camille Samuels
Denali Therapeutics and Vir Biotechnology, San Francisco, California, USA
Vicki L. Sato, PhD
Allergan, New York, New York, USA
Brent Saunders
Harvard University, Cambridge, Massachusetts, USA
David Scadden
Vir Biotechnology, San Francisco, California, USA
George Scangos, PhD
Geron Corporation, Menlo Park, California, USA
John A. Scarlett, MD
Scripps Research, Jupiter, Florida, and La Jolla, California, USA
Paul Schimmel
Broad Institute/Harvard University, Cambridge, Massachusetts, USA
Stuart L. Schreiber, PhD
Lyndra Therapeutics, Watertown, Massachusetts, USA
Amy Schulman
Seres Therapeutics, Cambridge, Massachusetts, USA
Eric Shaff
Koch Institute for Cancer Research, MIT, Cambridge, Massachusetts, USA
Phillip A. Sharp
Lewis Thomas Laboratory, Princeton University, Princeton, New Jersey USA
Thomas Shenk
Syros Pharmaceuticals, Cambridge, Massachusetts, USA
Nancy Simonian
Deerfield Management, New York, New York, USA
William Slattery
E-Scape Bio, Inc., San Francisco, California, USA
Julie A. Smith
OncoResponse, Inc., Seattle, Washington, USA
Clifford Stocks
ETH Zurich, Zurch, Switzerland
Markus Stoffel, MD
Decibel Therapeutics, Boston, Massachusetts, USA
Michael Su, PhD
EpiBone, Inc, New York, New York, USA
Nina Tandon
Healthcare, Life Sciences and Financial Services, Lincoln, Massachusetts, USA
Alison Taunton-Rigby, PhD, OBE
TRACON Pharmaceuticals, San Diego, California, USA
Charles Theuer, MD, PhD
Kallyope, New York, New York, USA
Nancy A. Thornberry
Alzheon, Framingham, Massachusetts, USA
Martin Tolar, MD PhD
Scripps Research, San Diego, California, USA
Eric Topol, MD
Decibel Therapeutics, Inc., Boston, Massachusetts, USA
Anna Trask
Quench Bio, Cambridge, Massachusetts, USA
Samantha Truex
The Rockefeller University, New York, New York, USA
Thomas Tuschl
Weill Cornell Medicine, New York, New York, USA
Harold E. Varmus
Flatiron Health, New York, New York, USA
Michael J. Vasconcelles, MD
Biogen, Cambridge, Massachusetts, USA
Michel Vounatsos
Horizon Therapeutics, Dublin, Ireland
Timothy P. Walbert
ChEM-H Institute, Stanford University, Stanford, California, USA
Christopher T. Walsh
Longwood Fund, Boston, Massachusetts, USA
Christoph Westphal, MD, PhD
Crinetics Pharmaceuticals, San Diego, California, USA
Wendell Wierenga, PhD
Codiak BioSciences, Cambridge, Massachusetts, USA
Douglas E. Williams, PhD
Walking Fish Therapeutics, San Francisco, California, USA
Lewis T. Williams
Theravance Biopharma, Inc., South San Francisco, California, USA
Rick E. Winningham
Zai Lab/Quan Capital, Shanghai, China
Peter Wirth
NGM Biopharmaceuticals, Inc., San Francisco, California, USA
David J. Woodhouse, PhD
Cerus Corporation, Concord, California, USA
Kleanthis G. Xanthopoulos, PhD
HHMI, RNA Therapeutics Institute at UMass Medical School, Worcester, Massachusetts, USA
Phillip D. Zamore, PhD
Johns Hopkins University (emeritus), Baltimore, Maryland, USA; National Institutes of Health; (2002-2008), Bethesda, Maryland, USA; Sanofi (former), Cambridge, Massachusetts, USA and Paris, France
Elias Zerhouni
HHMI/Broad Institute of MIT & Harvard/McGovern Institute for Brain Research at MIT Cambridge, Massachusetts, USA
Feng Zhang
*本文版权均属E药经理人所有，如需转载请在后台留言，经允许后方可转载，并在文首注明来源、作者。